Subscribe To

Price Alert Latest News Economic Calendar News

ALVO / Alvotech (ALVO) Q2 2022 Earnings Call Transcript

Alvotech (NASDAQ:ALVO ) Q2 2022 Earnings Conference Call September 1, 2022 8:00 AM ET Company Participants Benedict Stephan - Investor Relations Robert Wessman - Executive Chairman & Founder Mark Levick - Chief Executive Officer Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Ming Li - Chief Strategic Officer Conference Call Participants Tybalt Mornan - Morgan Stanley Karen Marchetti - Northland Jason Guerra - Bank of America Benedict Stephan [Call Started Abruptly] materials and some of our statements that we make today may include forward looking statements. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission, and the Nasdaq Iceland Stock Exchange. Read More

Demo Live Account See Partner Details

Content Topics

Alvotech

ALVO

2022

Earnings

Call

Transcript

alvo

Stock

Posted: Sep 1 2022, 14:16

Author Name: Seeking Alpha

ALVO News

By GlobeNewsWire
August 22, 2023

Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, annou

By Market Watch
July 24, 2023

Teva Pharmaceuticals and Alvotech expand biosimilars partnership

Teva Pharmaceuticals Industries Ltd. TEVA, +0.47% and Alvotech ALVO, +0.51% announced Monday that they are expanding their collaboration in the U.S. b

By The Motley Fool
June 30, 2023

Why Shares of Alvotech Are Jumping Friday

Alvotech specializes in biosimilar medicines. The company received a complete response letter from the FDA regarding the manufacturing facility for it

By Seeking Alpha
June 8, 2023

Alvotech: Precarious Cash Position Dilutes Special Situation Opportunity

Alvotech has a resolvable CRL. This took down the stock, but when resolved, that could create a quick spike. Ordinarily, this would be an opportunity,

By Zacks Investment Research
April 14, 2023

Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate

Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.

By GlobeNewsWire
March 17, 2023

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

Alvotech ( NASDAQ: ALVO ), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, to

By GlobeNewsWire
February 27, 2023

Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023

REYKJAVIK, Iceland, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture

By The Motley Fool
December 8, 2022

Why Shares of Alvotech Jumped This Week

The Icelandic biotech company has a deal to expand the reach of its Humira biosimilar in Eastern Europe.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.